UPC announces hearing details for Edwards Lifesciences
Edwards Lifesciences files application for provisional measures at UPC | Adds to existing hearings for 10x Genomics versus NanoString.
The Unified Patent Court (UPC) has announced another upcoming hearing at the Munich local division, set for September.
The latest hearing listed by the UPC concerns Edwards Lifesciences versus Meril GmbH and Meril Life Sciences Pvt Ltd, over a heart delivery system.
Edwards has filed an application for provisional measures against Meril.
The two medical technology companies have been involved in an abundance of legal disputes that span multiple jurisdictions and patents, including a total of four hearings scheduled at the new court.
The patent at issue in the latest hearing to be reported, number EP 3763331, relates to Edwards’ prosthetic valve cramping device.
Details of the Edwards v Meril hearing
The hearing will be held on October 10, 2023 (file number: ACT_550921/2023 UPC_CFI_249/2023)
It will begin at 9am and take place at Denisstraße 3, 2nd floor, hearing room 212 and overflow room 220b, 80335 Munich, Germany.
The language of the proceeding will be German. In total there are 13 local divisions of the Court of First Instance, with four being in Germany—Dusseldorf, Hamburg, Mannheim and Munich.
The remainder are located in Vienna, Brussels, Copenhagen, Helsinki, Paris, Milan, The Hague, Lisbon, and Ljubljana.
Previously announced hearings
On August 21, the UPC made its first announcement for scheduled hearings at the Munich Local Division.
These hearings concern applications for provisional measures in the dispute between 10x Genomics and others versus NanoString Technologies and others.
10x and NanoString are biotechnology research companies specialising in single-cell spatial transcriptomics (SST).
10x alleges that Nanostring’s CosMx products for ribonucleic acid (RNA) detection infringe its European patents and that Vizgen’s Merscope products infringe 10x patent, in multiple lawsuits.
The patents concerned are numbers 2 794 928 B1 and 4 108 782 B1 and relate to the in-situ detection of analytes.
According to its UPC filings, 10x is seeking “pan-European injunctive relief against the infringing activities of Nanostring and Vizgen across EU member states that are part of the new system”.
Did you enjoy reading this story? Sign up to our free daily newsletters and get stories sent like this straight to your inbox
